Navigation Links
Amicus Therapeutics Announces Third Quarter 2010 Financial Results
Date:11/8/2010

CRANBURY, N.J., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the quarter ended September 30, 2010, provided an update on its product development pipeline, including its Phase 3 program with Amigal (migalastat HCl) for the treatment of Fabry disease and reaffirmed the financial strength of the Company.  

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "During the third quarter we made significant progress further establishing Amicus as a leader in the research and development of new treatments for rare diseases.  Our strategic partnership with GSK not only supports the potential for success with the Amigal program but also provides us with multiple strategic options for continued growth.  Moving forward, we intend to judiciously invest in our pipeline and to explore a series of additional partnerships, all while ensuring that our financial strength allows us to fund our operations and capital expenditures through the anticipated U.S. commercial launch of Amigal."

Third Quarter Financial SummaryAs of September 30, 2010, Amicus held $57.6 million of cash, cash equivalents, and marketable securities.

For the three months ended September 30, 2010, Amicus reported a net loss of $15.4 million, or $0.56 per share attributable to common stockholders, compared to a net loss of $13.4 million, or $0.59 per share attributable to common stockholders for the same period in 2009.

Pipeline OverviewAmigal (migalastat HCl) for the Treatment of Fabry DiseaseOn October 29, 2010, Amicus announced a definitive agreement with GlaxoSmithKline PLC (GSK) to develop and commercialize Amigal™ (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease.  Under the terms of the agreement, GSK received an exclusive worldwide license to d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
2. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
3. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
4. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
5. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
6. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
7. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
8. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
9. Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
10. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe’s ... expertise to the Los Angeles County clinics including ... procedures are now being offered at all Healthpointe ... County, and San Bernardino County. , As ... neurons send electrical impulses throughout the body ...
(Date:5/29/2015)... May 29, 2015 The annual aesthetic meeting, ... (ASAPS), was held in Montreal from May 14-19th. This ... aesthetic professionals from around the world; dedicating itself exclusively to ... many renowned plastic surgeons to attend this year’s ... six-day event, Dr. Vitenas was given the honor of sitting ...
(Date:5/29/2015)... The FSH Society , the ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy ... FSHD Trial Preparedness Workshop. The Workshop, being held ... Rochester Medical Center in Rochester, New York, will ... world, including representatives from industry, the Food and ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The popular ... of their rewards based L-Style Select Program that gives ... program is limited to only 100 members per year, ... work one on one with fitness experts at Nuretix ... cost to them provided that they attain and maintain ...
(Date:5/29/2015)... NEW YORK (PRWEB) May 29, 2015 ... Medical Center has found that a urine test ... cancer with 92 percent accuracy. Dr. James McKiernan ... 2015 Annual Meeting Press Event. , Dr. ... John K. Lattimer Professor and chair of the ...
Breaking Medicine News(10 mins):Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 3Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 3
... ... before and after photos , ... 9, 2010 -- HCG True Diet offers new HCG Diet before and after photos and revamped ... navigation bar at the left hand of the site. The photos are taken of a ...
... HealthDay Reporter , THURSDAY, July 8 (HealthDay News) -- The ... smoke has slowed significantly, following dramatic drops starting in the ... percent of high school students still smoke, making it impossible ... among teens to 16 percent or less, the U.S. Centers ...
... ... career opportunities for ambitious professionals. , ... (PRWeb UK) July 9, 2010 -- HCL International, the leading global health and social ... GPs and social workers interested in working in Australia, at an invitation-only ...
... ... discovered a different kind of healing through writing down her emotions , ... Honolulu, HI (Vocus) July 9, 2010 -- She ... the release of Finally, it’s my time!, her new book made available through Xlibris, author ...
... ... new ways to make extra cash without having to spend big dollars. ... and beauty”. While most people cut back on certain luxuries during hard ... the recession. Youthful Trends is an innovative cosmetic company that is banking ...
... obese children have a 40 percent higher risk of ... obese have a 30 percent higher risk of GERD ... Permanente study published online in the International Journal ... establishes an association between obesity and GERD in children, ...
Cached Medicine News:Health News:See New HCG Diet Before and After Photos 2Health News:Decline in U.S. Teen Smoking Rate Stalls 2Health News:Decline in U.S. Teen Smoking Rate Stalls 3Health News:HCL International: Australia a Favourite Destination for UK Social Workers and GPs 2Health News:HCL International: Australia a Favourite Destination for UK Social Workers and GPs 3Health News:Moving On With A Pen 2Health News:Natural Cosmetic Company Offers Women Entrepreneurs a New Way to Make Money in Hard Times 2Health News:Natural Cosmetic Company Offers Women Entrepreneurs a New Way to Make Money in Hard Times 3Health News:Natural Cosmetic Company Offers Women Entrepreneurs a New Way to Make Money in Hard Times 4Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 2Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 3
... unit provides a convenient reservoir of cooling water for ... an extended period of time or in a location ... cool the hot side of the thermoelectric heat pump. ... which is adequate to run the 900R for up ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Inquire...
Inquire...
Medicine Products: